SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: juneau_boy who wrote (411)3/12/2000 1:15:00 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3559
 
<<. Did I misunderstand are you still long ISIS? If so, do you have a theory on what went wrong with Crohn's 2302? >>

I bailed out of ISIP in late '98. No position now and will not have for some time.

2302 failed because of the narrow therapeutic window and drug pharmacokinetic. ICAM-1 is good (if selective) target for inflammatory diseases.

Miljenko